For research use only. Not for therapeutic Use.
S07-1066(CAT: I040892) is a potent inhibitor of aldo-keto reductase 1C3 (AKR1C3), an enzyme involved in drug metabolism and resistance. By selectively blocking AKR1C3-mediated reduction of doxorubicin (DOX), S07-1066 enhances the cytotoxic effects of DOX, overcoming resistance in cells that overexpress AKR1C3. This synergistic action not only potentiates the efficacy of DOX in resistant cancer cells but also provides a potential strategy for treating cancers that exhibit AKR1C3-mediated drug resistance. S07-1066 can be used in Cancer Disease Research, particularly in studies focused on overcoming chemotherapy resistance and improving the effectiveness of doxorubicin in cancer treatment.
CAS Number | 876625-29-5 |
Synonyms | 1-[4-(3,5-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid |
Molecular Formula | C16H11Cl2FO2 |
Purity | ≥95% |
IUPAC Name | 1-[4-(3,5-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid |
InChI | InChI=1S/C16H11Cl2FO2/c17-11-5-9(6-12(18)8-11)13-2-1-10(7-14(13)19)16(3-4-16)15(20)21/h1-2,5-8H,3-4H2,(H,20,21) |
InChIKey | DFJGLZRYGZSQOR-UHFFFAOYSA-N |
SMILES | C1CC1(C2=CC(=C(C=C2)C3=CC(=CC(=C3)Cl)Cl)F)C(=O)O |